{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:52Z","timestamp":1793817592492,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019450","name":"Verastem Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019450","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mexican Government"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma that is incurable with existing therapies, and therefore presents a significant unmet clinical need. The ability of this disease to overcome therapy, including those that target the B cell receptor pathway which has a pathogenic role in MCL, highlights the need to develop new treatment strategies. Herein, we demonstrate that a distinguishing feature of lymph node resident MCL cells is the expression of phosphatidylinositol 3-kinase \u03b3 (PI3K\u03b3), a PI3K isoform that is not highly expressed in other B cells or B-cell malignancies. By exploring the role of PI3K in MCL using different PI3K isoform inhibitors, we provide evidence that duvelisib, a dual PI3K\u03b4\/\u03b3 inhibitor, has a greater effect than PI3K\u03b4- and PI3K\u03b3-selective inhibitors in blocking the proliferation of primary MCL cells and MCL cell lines, and in inhibiting tumour growth in a mouse xenograft model. In addition, we demonstrated that PI3K\u03b4\/\u03b3 signalling is critical for migration of primary MCL cells and cell lines. Our data indicates that aberrant expression of PI3K\u03b3 is a critical feature of MCL pathogenesis. Thus, we suggest that the dual PI3K\u03b4\/\u03b3 duvelisib would be effective for the treatment of mantle cell lymphoma.<\/jats:p>","DOI":"10.1038\/s41598-023-30148-3","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T10:03:06Z","timestamp":1678183386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Roles of PI3K\u03b3 and PI3K\u03b4 in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3K\u03b3\/\u03b4 inhibitor duvelisib"],"prefix":"10.1038","volume":"13","author":[{"given":"Kathleen J.","family":"Till","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahera","family":"Alnassfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallardo Zapata","family":"Janet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Pachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Slupsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"30148_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah, C. Y., Seymour, J. F. & Wang, M. L. Mantle cell lymphoma. J. Clin. Oncol. 34, 1256\u20131269. https:\/\/doi.org\/10.1200\/JCO.2015.63.5904 (2016).","journal-title":"J. Clin. Oncol."},{"key":"30148_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks, K. Update on mantle cell lymphoma. Blood 132, 1647\u20131656. https:\/\/doi.org\/10.1182\/blood-2018-03-791392 (2018).","journal-title":"Blood"},{"key":"30148_CR3","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2018","unstructured":"Rule, S. et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: Extended 3.5-year follow-up from a pooled analysis. Haematologica 104, e211\u2013e214. https:\/\/doi.org\/10.3324\/haematol.2018.205229 (2018).","journal-title":"Haematologica"},{"key":"30148_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jha2.311","volume":"3","author":"T Alnassfan","year":"2021","unstructured":"Alnassfan, T., Cox-Pridmore, M. J., Taktak, A. & Till, K. J. Mantle cell lymphoma treatment options for elderly\/unfit patients: A systematic review. eJHaem 3, 276\u2013290. https:\/\/doi.org\/10.1002\/jha2.311 (2021).","journal-title":"eJHaem"},{"key":"30148_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","volume":"132","author":"G Clot","year":"2018","unstructured":"Clot, G. et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 132, 413\u2013422. https:\/\/doi.org\/10.1182\/blood-2018-03-838136 (2018).","journal-title":"Blood"},{"key":"30148_CR6","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Investig. 122, 3416\u20133423. https:\/\/doi.org\/10.1172\/JCI61272 (2012).","journal-title":"J. Clin. Investig."},{"key":"30148_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1080\/10428194.2019.1571205","volume":"60","author":"BS Kahl","year":"2019","unstructured":"Kahl, B. S. et al. Recent advances and future directions in mantle cell lymphoma research: Report of the 2018 mantle cell lymphoma consortium workshop. Leuk. Lymphoma 60, 1853\u20131865. https:\/\/doi.org\/10.1080\/10428194.2019.1571205 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"30148_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-017-0533-9","volume":"10","author":"M Fichtner","year":"2017","unstructured":"Fichtner, M., Dreyling, M., Binder, M. & Trepel, M. The role of B cell antigen receptors in mantle cell lymphoma. J. Hematol. Oncol. 10, 164. https:\/\/doi.org\/10.1186\/s13045-017-0533-9 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"30148_CR9","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","volume":"131","author":"XS Puente","year":"2018","unstructured":"Puente, X. S., Jares, P. & Campo, E. Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions. Blood 131, 2283\u20132296. https:\/\/doi.org\/10.1182\/blood-2017-10-764373 (2018).","journal-title":"Blood"},{"key":"30148_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","volume":"130","author":"P Balsas","year":"2017","unstructured":"Balsas, P. et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood 130, 501\u2013513. https:\/\/doi.org\/10.1182\/blood-2017-04-776740 (2017).","journal-title":"Blood"},{"key":"30148_CR11","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood-2018-02-832535","volume":"131","author":"PY Kuo","year":"2018","unstructured":"Kuo, P. Y. et al. SOX11 augments BCR signaling to drive MCL-like tumor development. Blood 131, 2247\u20132255. https:\/\/doi.org\/10.1182\/blood-2018-02-832535 (2018).","journal-title":"Blood"},{"key":"30148_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","volume":"34","author":"C Pighi","year":"2011","unstructured":"Pighi, C. et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell. Oncol. 34, 141\u2013153. https:\/\/doi.org\/10.1007\/s13402-011-0019-7 (2011).","journal-title":"Cell. Oncol."},{"key":"30148_CR13","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl, B. S. et al. A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood 123, 3398\u20133405. https:\/\/doi.org\/10.1182\/blood-2013-11-537555 (2014).","journal-title":"Blood"},{"key":"30148_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220 (2013).","journal-title":"N. Engl. J. Med."},{"key":"30148_CR15","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood.2019852368","volume":"133","author":"TE Witzig","year":"2019","unstructured":"Witzig, T. E. & Inwards, D. Acalabrutinib for mantle cell lymphoma. Blood 133, 2570\u20132574. https:\/\/doi.org\/10.1182\/blood.2019852368 (2019).","journal-title":"Blood"},{"key":"30148_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.blre.2017.08.002","volume":"31","author":"M van den Brand","year":"2017","unstructured":"van den Brand, M., Scheijen, B., Hess, C. J., van Krieken, J. H. J. & Groenen, P. Pathways towards indolent B-cell lymphoma\u2014Etiology and therapeutic strategies. Blood Rev. 31, 426\u2013435. https:\/\/doi.org\/10.1016\/j.blre.2017.08.002 (2017).","journal-title":"Blood Rev."},{"key":"30148_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2015.139493","volume":"101","author":"NH Fowler","year":"2016","unstructured":"Fowler, N. H. et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101, 531\u2013540. https:\/\/doi.org\/10.3324\/haematol.2015.139493 (2016).","journal-title":"Haematologica"},{"key":"30148_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.semcancer.2011.09.006","volume":"21","author":"JA Burger","year":"2011","unstructured":"Burger, J. A. & Ford, R. J. The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies. Semin. Cancer Biol. 21, 308\u2013312. https:\/\/doi.org\/10.1016\/j.semcancer.2011.09.006 (2011).","journal-title":"Semin. Cancer Biol."},{"key":"30148_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.leu.2401664","volume":"14","author":"R Castillo","year":"2000","unstructured":"Castillo, R. et al. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 14, 292\u2013298. https:\/\/doi.org\/10.1038\/sj.leu.2401664 (2000).","journal-title":"Leukemia"},{"key":"30148_CR20","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/ijc.29326","volume":"136","author":"S Bernard","year":"2014","unstructured":"Bernard, S. et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int. J. Cancer 136, 2761\u20132774. https:\/\/doi.org\/10.1002\/ijc.29326 (2014).","journal-title":"Int. J. Cancer"},{"key":"30148_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-015-0157-x","volume":"8","author":"R Maffei","year":"2015","unstructured":"Maffei, R. et al. Targeting neoplastic B cells and harnessing microenvironment: The \u201cdouble face\u201d of ibrutinib and idelalisib. J. Hematol. Oncol. 8, 60. https:\/\/doi.org\/10.1186\/s13045-015-0157-x (2015).","journal-title":"J. Hematol. Oncol."},{"key":"30148_CR22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2015-01-624585","volume":"126","author":"S Bhatt","year":"2015","unstructured":"Bhatt, S. et al. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood 126, 1555\u20131564. https:\/\/doi.org\/10.1182\/blood-2015-01-624585 (2015).","journal-title":"Blood"},{"key":"30148_CR23","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1038\/onc.2014.403","volume":"34","author":"KH Shain","year":"2015","unstructured":"Shain, K. H., Dalton, W. S. & Tao, J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 34, 4673\u20134682. https:\/\/doi.org\/10.1038\/onc.2014.403 (2015).","journal-title":"Oncogene"},{"key":"30148_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14, 517\u2013534. https:\/\/doi.org\/10.1038\/nrc3774 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"30148_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba, N. S. et al. Pathogenic role of B-cell receptor signaling and canonical NF-kB activation in mantle cell lymphoma. Blood 128, 82\u201392. https:\/\/doi.org\/10.1182\/blood-2015-11-681460 (2016).","journal-title":"Blood"},{"key":"30148_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41419-017-0157-6","volume":"9","author":"H Rauert-Wunderlich","year":"2018","unstructured":"Rauert-Wunderlich, H., Rudelius, M., Berberich, I. & Rosenwald, A. CD40L mediated alternative NFkB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 9, 86. https:\/\/doi.org\/10.1038\/s41419-017-0157-6 (2018).","journal-title":"Cell Death Dis."},{"key":"30148_CR27","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","volume":"124","author":"S Dong","year":"2014","unstructured":"Dong, S. et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124, 3583\u20133586. https:\/\/doi.org\/10.1182\/blood-2014-07-587279 (2014).","journal-title":"Blood"},{"key":"30148_CR28","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/leu.2015.105","volume":"29","author":"K Balakrishnan","year":"2015","unstructured":"Balakrishnan, K. et al. The phosphoinositide-3-kinase (PI3K)-\u03b4 and \u03b3 inhibitor, IPI-145, overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL. Leukemia 29, 1811\u20131822. https:\/\/doi.org\/10.1038\/leu.2015.105 (2015).","journal-title":"Leukemia"},{"key":"30148_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/2326-6066.cir-17-0143","volume":"5","author":"P Foubert","year":"2017","unstructured":"Foubert, P., Kaneda, M. M. & Varner, J. A. PI3K\u03b3 activates integrin \u03b14 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol. Res. 5, 957\u2013968. https:\/\/doi.org\/10.1158\/2326-6066.cir-17-0143 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"30148_CR30","doi-asserted-by":"publisher","first-page":"e60226","DOI":"10.1371\/journal.pone.0060226","volume":"8","author":"MC Schmid","year":"2013","unstructured":"Schmid, M. C. et al. PI3-kinase \u03b3 promotes Rap1a-mediated activation of myeloid cell integrin \u03b14\u03b21, leading to tumor inflammation and growth. PLoS ONE 8, e60226. https:\/\/doi.org\/10.1371\/journal.pone.0060226 (2013).","journal-title":"PLoS ONE"},{"key":"30148_CR31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/ajh.25228","volume":"93","author":"IW Flinn","year":"2018","unstructured":"Flinn, I. W. et al. Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am. J. Hematol. 93, 1311\u20131317. https:\/\/doi.org\/10.1002\/ajh.25228 (2018).","journal-title":"Am. J. Hematol."},{"key":"30148_CR32","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","volume":"111","author":"PG Longo","year":"2008","unstructured":"Longo, P. G. et al. The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B cell receptor in chronic lymphocytic leukemia B cells. Blood 111, 846\u2013855. https:\/\/doi.org\/10.1182\/blood-2007-05-089037 (2008).","journal-title":"Blood"},{"key":"30148_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjh.12498","volume":"163","author":"J Bodo","year":"2013","unstructured":"Bodo, J. et al. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br. J. Haematol. 163, 72\u201380. https:\/\/doi.org\/10.1111\/bjh.12498 (2013).","journal-title":"Br. J. Haematol."},{"key":"30148_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"IW Flinn","year":"2017","unstructured":"Flinn, I. W. et al. Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4\/\u03b3 is clinically active in advanced hematologic malignancies. Blood 131, 877\u2013887. https:\/\/doi.org\/10.1182\/blood-2017-05-786566 (2017).","journal-title":"Blood"},{"key":"30148_CR35","doi-asserted-by":"publisher","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao, X. et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat. Commun. 8, 14920. https:\/\/doi.org\/10.1038\/ncomms14920 (2017).","journal-title":"Nat. Commun."},{"key":"30148_CR36","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","volume":"121","author":"S Iyengar","year":"2013","unstructured":"Iyengar, S. et al. p110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 121, 2274\u20132284. https:\/\/doi.org\/10.1182\/blood-2012-10-460832 (2013).","journal-title":"Blood"},{"key":"30148_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1034\/j.1600-065x.2000.17712.x","volume":"177","author":"Y Sotsios","year":"2000","unstructured":"Sotsios, Y. & Ward, S. G. Phosphoinositide 3-kinase: A key biochemical signal for cell migration response to chemokines. Immunol. Rev. 177, 217\u2013235. https:\/\/doi.org\/10.1034\/j.1600-065x.2000.17712.x (2000).","journal-title":"Immunol. Rev."},{"key":"30148_CR38","doi-asserted-by":"publisher","first-page":"43273","DOI":"10.1074\/jbc.M402924200","volume":"279","author":"C Weiss-Haljiti","year":"2004","unstructured":"Weiss-Haljiti, C. et al. Involvement of PI3K\u03b3, Rac & PAK signaling in chemokine-induced macrophage migration. J. Biol. Chem. 279, 43273\u201343284. https:\/\/doi.org\/10.1074\/jbc.M402924200 (2004).","journal-title":"J. Biol. Chem."},{"key":"30148_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","volume":"99","author":"R Forster","year":"1999","unstructured":"Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23\u201333 (1999).","journal-title":"Cell"},{"key":"30148_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1034\/j.1600-065X.2003.00073.x","volume":"195","author":"G Muller","year":"2003","unstructured":"Muller, G., Hopken, U. E. & Lipp, M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol. Rev. 195, 117\u2013135 (2003).","journal-title":"Immunol. Rev."},{"key":"30148_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1034\/j.1600-065X.2000.00618.x","volume":"176","author":"JG Cyster","year":"2000","unstructured":"Cyster, J. G. et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol. Rev. 176, 181\u2013193 (2000).","journal-title":"Immunol. Rev."},{"key":"30148_CR42","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1084\/jem.20041185","volume":"200","author":"Y Nie","year":"2004","unstructured":"Nie, Y. et al. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J. Exp. Med. 200, 1145\u20131156 (2004).","journal-title":"J. Exp. Med."},{"key":"30148_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.20021477","volume":"197","author":"AM Glodek","year":"2003","unstructured":"Glodek, A. M., Honczarenko, M., Le, Y., Campbell, C. J. & Silberstein, L. E. Sustained activation of cell adhesion is a differentially regulated process in B lymphopoiesis. J. Exp. Med. 197, 461\u2013473 (2003).","journal-title":"J. Exp. Med."},{"key":"30148_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-015-0004-3","volume":"4","author":"S Middle","year":"2015","unstructured":"Middle, S. et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin\u2019s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp. Hematol. Oncol. 4, 10. https:\/\/doi.org\/10.1186\/s40164-015-0004-3 (2015).","journal-title":"Exp. Hematol. Oncol."},{"key":"30148_CR45","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova, A. V., Tamayo, A. T., Ford, R. J. & Burger, J. A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604\u20134613. https:\/\/doi.org\/10.1182\/blood-2008-10-185827 (2009).","journal-title":"Blood"},{"key":"30148_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/10739680600776062","volume":"13","author":"AM Ferreira","year":"2006","unstructured":"Ferreira, A. M., Isaacs, H., Hayflick, J. S., Rogers, K. A. & Sandig, M. The p110delta isoform of PI3K differentially regulates beta1 and beta2 integrin-mediated monocyte adhesion and spreading and modulates diapedesis. Microcirculation 13, 439\u2013456. https:\/\/doi.org\/10.1080\/10739680600776062 (2006).","journal-title":"Microcirculation"},{"key":"30148_CR47","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27, 5497\u20135510. https:\/\/doi.org\/10.1038\/onc.2008.245 (2008).","journal-title":"Oncogene"},{"key":"30148_CR48","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","volume":"32","author":"AY Ali","year":"2018","unstructured":"Ali, A. Y. et al. Distinct roles for phosphoinositide 3-kinases \u03b3 and \u03b4 in malignant B cell migration. Leukemia 32, 1958\u20131969. https:\/\/doi.org\/10.1038\/s41375-018-0012-5 (2018).","journal-title":"Leukemia"},{"key":"30148_CR49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","volume":"5","author":"P Foubert","year":"2017","unstructured":"Foubert, P., Kaneda, M. M. & Varner, J. A. PI3K\u03b3 activates integrin \u03b14 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol. Res. 5, 957\u2013968. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0143 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"30148_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442. https:\/\/doi.org\/10.1038\/nature19834 (2016).","journal-title":"Nature"},{"key":"30148_CR51","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","volume":"111","author":"J Dal Col","year":"2008","unstructured":"Dal Col, J. et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111, 5142\u20135151. https:\/\/doi.org\/10.1182\/blood-2007-07-103481 (2008).","journal-title":"Blood"},{"key":"30148_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10409238.2016.1215288","volume":"51","author":"J Jellusova","year":"2016","unstructured":"Jellusova, J. & Rickert, R. C. The PI3K pathway in B cell metabolism. Crit. Rev. Biochem. Mol. Biol. 51, 359\u2013378. https:\/\/doi.org\/10.1080\/10409238.2016.1215288 (2016).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"30148_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1158\/1078-0432.CCR-15-3135","volume":"23","author":"Q Yang","year":"2017","unstructured":"Yang, Q. et al. Idelalisib impacts cell growth through inhibiting translation-regulatory mechanisms in mantle cell lymphoma. Clin. Cancer Res. 23, 181\u2013192. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3135 (2017).","journal-title":"Clin. Cancer Res."},{"key":"30148_CR54","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.4049\/jimmunol.1402304","volume":"194","author":"KJ Till","year":"2015","unstructured":"Till, K. J., Pettitt, A. R. & Slupsky, J. R. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase delta but not SYK or BTK in chronic lymphocytic leukemia cells. J. Immunol. 194, 2439\u20132446. https:\/\/doi.org\/10.4049\/jimmunol.1402304 (2015).","journal-title":"J. Immunol."},{"key":"30148_CR55","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling, M. et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann. Oncol. 28, 2169\u20132178. https:\/\/doi.org\/10.1093\/annonc\/mdx289 (2017).","journal-title":"Ann. Oncol."},{"key":"30148_CR56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","volume":"4","author":"C Tarantelli","year":"2020","unstructured":"Tarantelli, C. et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Adv. 4, 819\u2013829. https:\/\/doi.org\/10.1182\/bloodadvances.2019000844 (2020).","journal-title":"Blood Adv."},{"key":"30148_CR57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjh.15108","volume":"181","author":"O Hershkovitz-Rokah","year":"2018","unstructured":"Hershkovitz-Rokah, O., Pulver, D., Lenz, G. & Shpilberg, O. Ibrutinib resistance in mantle cell lymphoma: Clinical, molecular and treatment aspects. Br. J. Haematol. 181, 306\u2013319. https:\/\/doi.org\/10.1111\/bjh.15108 (2018).","journal-title":"Br. J. Haematol."},{"key":"30148_CR58","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1042\/BCJ20220440","volume":"479","author":"HR Warren","year":"2022","unstructured":"Warren, H. R., Ross, S. J., Smith, P. D., Coulson, J. M. & Prior, I. A. Combinatorial approaches for mitigating resistance to KRAS-targeted therapies. Biochem. J. 479, 1985\u20131997. https:\/\/doi.org\/10.1042\/BCJ20220440 (2022).","journal-title":"Biochem. J."},{"key":"30148_CR59","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/14656566.2020.1751123","volume":"21","author":"AM Frustaci","year":"2020","unstructured":"Frustaci, A. M. et al. Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opin. Pharmacother. 21, 1299\u20131309. https:\/\/doi.org\/10.1080\/14656566.2020.1751123 (2020).","journal-title":"Expert Opin. Pharmacother."},{"key":"30148_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3324\/haematol.2022.281266","volume":"108","author":"SS Skanland","year":"2023","unstructured":"Skanland, S. S. & Brown, J. R. PI3K inhibitors in chronic lymphocytic leukemia: Where do we go from here?. Haematologica 108, 9\u201321. https:\/\/doi.org\/10.3324\/haematol.2022.281266 (2023).","journal-title":"Haematologica"},{"key":"30148_CR61","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.3324\/haematol.2018.194399","volume":"103","author":"CW Eskelund","year":"2018","unstructured":"Eskelund, C. W. et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica 103, e541\u2013e543. https:\/\/doi.org\/10.3324\/haematol.2018.194399 (2018).","journal-title":"Haematologica"},{"key":"30148_CR62","first-page":"40","volume":"91","author":"A Zam\u00f2","year":"2006","unstructured":"Zam\u00f2, A. et al. Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica 91, 40\u201347 (2006).","journal-title":"Haematologica"},{"key":"30148_CR63","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0145-2126(02)00013-9","volume":"26","author":"R Lai","year":"2002","unstructured":"Lai, R. et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk. Res. 26, 849\u2013855. https:\/\/doi.org\/10.1016\/S0145-2126(02)00013-9 (2002).","journal-title":"Leuk. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30148-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30148-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30148-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:15:45Z","timestamp":1678187745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30148-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["30148"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-30148-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KJT, JRS and ARP received funding from Verastem Oncology to conduct this study. SC, DTW and JAP are employees of Verastem Oncology. All other authors do not have any conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3793"}}